Walmart halts H-1B visa offers amid Trump’s $100,000 fee increase - Bloomberg
Investing.com - Cantor Fitzgerald maintained its Overweight rating and $10.00 price target on Artiva Biotherapeutics (NASDAQ:ARTV), representing significant upside from the current price of $2.77, following the company’s announcement on its allogeneic natural killer (Allo-NK) cell therapy program. According to InvestingPro data, analyst targets range from $10 to $19, suggesting strong potential despite the stock’s 78% decline over the past year.
Artiva reported that over 20 patients have been treated with its Allo-NK approach across approximately 12 centers, demonstrating strong enrollment pace and acceptance of the lymphodepletion protocol in community settings. InvestingPro analysis shows the company maintains a FAIR financial health score, with sufficient liquid assets exceeding short-term obligations, though it is currently burning through cash reserves.
The company plans to present data in November showing "uniform, consistent and deep B-cell depletion" with its therapy, which Cantor Fitzgerald suggests indicates substantially deeper B-cell depletion than what would typically be achieved with CD20 monoclonal antibody treatment alone, despite the protocol including Rituxan.
Artiva also noted favorable tolerability results to date, further supporting the therapy’s potential viability in community treatment settings, according to the company’s press release.
The biotech firm will share additional data from more than 15 treated rheumatoid arthritis patients in the first half of 2026, including several with six-month or longer follow-up, and plans to seek FDA feedback for a potential pivotal trial design during the same period.
In other recent news, Artiva Biotherapeutics announced that its cell therapy candidate, AlloNK, has received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of refractory rheumatoid arthritis in combination with rituximab. This development marks AlloNK as the first drug candidate in the deep B-cell depleting therapeutic category to achieve such a designation for this condition. Artiva Biotherapeutics has prioritized refractory rheumatoid arthritis as the lead indication for AlloNK, aiming to enhance B-cell-targeting antibodies through antibody-dependent cellular cytotoxicity. The company’s decision to focus on this condition comes as part of its strategic clinical development program for AlloNK, also known as AB-101. The Fast Track status is intended to expedite the review process, potentially bringing this treatment to patients sooner. Artiva Biotherapeutics’ announcement has been met with significant interest from investors and industry observers alike.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.